Many patients enrolled in phase 3 trials had positive serologies at their screening visit (and were hence excluded from the data analysis). We can only assume the general population reflects this phenomenon.
Interestingly, visit 1 of the Moderna phase 3 trial allowed dosing of patients before labs were back, meaning many previously infected (unknowingly) patients were given one dose. They did fine, and no concerning safety signal was apparent in those patients.
So I agree that if a patient has confirmed prior infection, the vaccine isn’t likely critical to address community health. That said,
https://www.cougarboard.com/board/message.html?id=25186807